UNSPSC 51183706: Pioglitazone hydrochloride

This classification denotes a hypoglycemic agent with the molecular formula C19H20N2O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JQT35NPK6C, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)- but more generally known as pioglitazone hydrochloride, which bears US NIH Compound Identifier 4829. European Medicines Agency schedules Pioglitazone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03834MIG.

UNSPSC 51183706 Pioglitazone hydrochloride, a Commodity code, covers the supply of generic pharmaceuticals and over-the-counter products to state and local government facilities through established wholesaler networks. State and local governments procure this code through multi-state cooperative purchasing alliances and individual state health departments seeking to supply hospitals, clinics, correctional facilities, and other public health institutions with cost-competitive generic medications. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body under this code, aggregating demand across participating states and their subordinate agencies.

MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The procurement covers participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), comply with cGMP and Drug Supply Chain Security Act standards, and submit detailed product information organized by National Drug Code, SKU, UPC, strength, dosage form, and manufacturing location. Evaluation is weighted heavily toward price competitiveness (75 percent), with secondary criteria addressing compliance with administrative data format requirements, EDI capability, and agreement to a 3 percent administrative fee. Contract awards are effective July 1, 2026, for two years with optional extensions, and vendors must maintain comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy coverage.